Seeking Alpha

E. I. du Pont de Nemours and Company (DuPont) (DD)

  • Fri, Oct. 2, 4:13 PM
    • Du Pont (DD +1.9%) could face punitive damages in a trial involving an Ohio woman who says she got kidney cancer from contaminated water.
    • A judge ruled against a motion by the company to find that punitive damages might apply. The case may help settle thousands of similar suits related to the company's dumping of the chemical C8 -- used in making Teflon -- into area drinking water.
    • Plaintiff Clara Bartlett says that Du Pont knew there were risks from the chemical that the company didn't share with the public. Du Pont's chief scientist testified Thursday that he was tracking potential problems with C8 but didn't know until 2012 that it could cause several diseases.
    | Fri, Oct. 2, 4:13 PM | 5 Comments
  • Wed, Sep. 30, 11:59 AM
    • Federal investigators have found broad safety problems at DuPont's (DD +1.5%) La Porte, Tex., plant where four workers died last year from exposure to a toxic gas, according to a report from the U.S. Chemical Safety Board.
    • The unit where the workers died did not having adequate ventilation or air monitoring to ensure worker safety, and procedures were not followed that would have restricted worker access to areas where ventilation fans were not working, according to the report.
    • A review by DuPont of systems at the plant that control overpressure in equipment is in the fourth year of a five-year assessment, but is only 35% complete, according to the board.
    | Wed, Sep. 30, 11:59 AM | 9 Comments
  • Mon, Sep. 28, 12:58 PM
    • Huntsman (HUN -23.8%) plunges by nearly 25% following an earnings warning from the company after Friday's market close that lower titanium dioxide pricing, currency headwinds, soft demand in Asia, lower oil prices and a delay in benefits from lower raw material prices will negatively impact Q3 earnings.
    • HUN says it also sees lower margins for methyl tertiary butyl ether due to lower oil prices and forecast continued lower MDI urethane component product margins in the Asia Pacific region.
    • CEO Peter Huntsman says he is "optimistic about the future" despite the short-term headwinds, and that the company anticipates Q4 adjusted EBITDA similar to Q3 at ~$300M, similar to last year's level; HUN also remains committed to a separation of the pigments and additives business by year-end 2016 or sooner.
    • Other chemical companies also are lower: DOW -2.7%, DD -1.7%, EMN -4%, ASH -4.3%, CC -7.6%, KRO -1%, SHLM -3.1%, LYB -4.1%, SSL -4%, OTCQX:BASFY -1.3%.
    | Mon, Sep. 28, 12:58 PM | 7 Comments
  • Mon, Sep. 14, 9:59 AM
    • DuPont (DD -1%) today will face the first trial in litigation from residents near one of its plants in West Virginia who have accused it of sickening them with a toxic chemical that leaked into their drinking water.
    • While DuPont is the named defendant, the recent performance chemicals spinoff Chemours (CC -2.4%) will cover Dupont's potential liability.
    • Plaintiffs say DuPont used perfluorooctanoic acid, known as C-8, at the company's Washington Works plant in Parkersburg, W. Va., since the 1950s and continued even after learning it was potentially toxic and that it had been discovered in nearby drinking water supplies in Ohio and West Virginia.
    | Mon, Sep. 14, 9:59 AM | 9 Comments
  • Fri, Aug. 14, 8:58 AM
    • DuPont (NYSE:DD) +1.8% premarket after J.P. Morgan upgrades shares to Overweight from Neutral with a $60 price target, up from $58, citing a positive risk/reward profile after five years of underperforming the market despite lingering negative conditions in the chemicals industry.
    • "High-quality agricultural companies have received high-teens EBITDA bids, which we read as a rough marker of intrinsic value," JPM says, adding that DuPont's plans to repurchase shares worth $4B over the next 18 months may offer "stability or strength to the share price."
    • The firm says the referendum on DuPont's performance sought by activist investor Nelson Peltz that was settled by a vote of confidence in management is a positive for the stock, and "management is now in a position to demonstrate that the confidence of its shareholder base was well-placed."
    | Fri, Aug. 14, 8:58 AM | 11 Comments
  • Thu, Jul. 2, 3:29 PM
    • DuPont (DD -2.4%) drops to a new 52-week low after completing the spinoff of its Chemours performance chemicals business, which has been criticized by many analysts.
    • RBC maintains its Sector Perform rating but cuts its price target to $64 from $69, saying DD still faces significant forex and other headwinds in many of its remaining businesses; the firm believes DD is fully valued at 9.7x its new post-spin estimated 2016 EBITDA.
    • Wells Fargo has a somewhat more favorable view on the transaction, believing it enables DD to dampen earnings cyclicality in its quest to be a science company
    | Thu, Jul. 2, 3:29 PM | 35 Comments
  • Wed, Jun. 24, 12:41 PM
    • DuPont (DD -2.6%) is the Dow's biggest percentage loser after J.P. Morgan provided a downbeat assessment of Chemours, the performance chemicals division DuPont is spinning off.
    • The firm starts coverage of Chemours with an Underweight rating, believing the spinoff is a "fully-valued security," and that the company will decide to cut its dividend.
    • JPM expects Chemours' cash flow generation to be negligible for 2015, so the company would have to borrow to pay the initial quarterly dividend of $100M and is not likely to generate enough capital to sustain such a dividend payment.
    • Credit Suisse agrees, adding that Chemours is saddled with large legal liabilities, mainly from production of fluoropolymer products such as Teflon, which faces suits and environmental fines of $295M with the potential to more than double.
    | Wed, Jun. 24, 12:41 PM | 30 Comments
  • Wed, May 13, 2:15 PM
    • DuPont (DD -6%) remains sharply lower after Nelson Peltz's Trian Fund Management lost its proxy fight and failed to get any of its nominees elected to the company's board, and Citigroup analysts agree that it's not good news.
    • Although Trian lost, Citi thinks DuPont will be under greater shareholder scrutiny going forward even though the result was a big win for CEO Ellen Kullman and management, with cost reductions and share repurchases taking the primary focus in the near-term.
    • DuPont also "may have to play more offense" in agriculture after spending the last several months playing defense in the proxy battle; the firm says it sees logic in combining DD's and Dow Chemical's (NYSE:DOW) ag businesses.
    • Trian may not be patient and may exit its position over time, offering a potential overhang on DD shares, Citi says.
    | Wed, May 13, 2:15 PM | 23 Comments
  • Wed, May 13, 9:15 AM
    | Wed, May 13, 9:15 AM | 1 Comment
  • Wed, May 13, 9:07 AM
    • It appears that Trian nominees were not elected to the DuPont (NYSE:DD) Board at today's annual meeting of stockholders.
    • "The vote was close. We greatly appreciate the support we received from the vast majority of institutional well as the leading proxy advisory firms, who all recognize the need for change at DuPont," Trian said in a statement.
    • DD -6.2% premarket
    | Wed, May 13, 9:07 AM | 14 Comments
  • Wed, May 13, 8:40 AM
    • DuPont (NYSE:DD)  was seen winning its proxy fight against activist investor Nelson Peltz, sources told CNBC, although the vote is said to be very close.
    • The annual shareholder meeting at DuPont's Chestnut Run headquarters has begun.
    • Previously: DuPont-Trian battle comes to a head (May. 13 2015)
    • DD -3.1% premarket
    | Wed, May 13, 8:40 AM | 7 Comments
  • Mon, Apr. 27, 10:45 AM
    • Shareholder proxy firm ISS recommends activist investor Nelson Peltz for a spot on DuPont's (DD +3.1%) board, plus one other nominee put forward by Peltz's Trian Fund Management.
    • "This is not a broken company - but there is compelling evidence that the dissidents are onto something in their critique," ISS says following last week's release of disappointing Q1 results.
    • DuPont and Trian have tried to make offers to settle the increasingly bitter proxy fight over the company's future, but both sides have been steadfast on whether Peltz deserves a seat on the board.
    | Mon, Apr. 27, 10:45 AM | 2 Comments
  • Tue, Apr. 21, 3:13 PM
    • DuPont's (DD -2.7%) disappointing Q1 revenue and reduced 2015 earnings outlook is expected to provide fresh ammunition to Nelson Peltz in his campaign to split up the company.
    • Peltz's Trian Fund will point to the lower outlook - DuPont now sees FY 2015 EPS at the low end of $4.00-$4.20 vs. $4.06 analyst consensus estimate - as further evidence that the company fails to meet its financial targets, SunTrust's James Sheehan says, adding that the profit warning would "likely intensify the debate."
    • DuPont, which gets ~60% of its sales from outside the U.S., blames a stronger dollar for the 9% drop in Q1 sales and reduced profit outlook, but says cost-cutting efforts are helping the bottom-line.
    • Leading shareholder proxy firm ISS is meeting with Peltz and DuPont on Wednesday and is expected to make its recommendation by the end of the month; the battle will come to a head on May 13, when DuPont holds its annual shareholder meeting.
    | Tue, Apr. 21, 3:13 PM | 6 Comments
  • Tue, Apr. 21, 7:25 AM
    • Net income of $1.03B vs. $1.44B in the same quarter a year ago. Excluding pension costs and other items, operating earnings were $1.34 a share, down from $1.58 per share, the prior year.
    • Cost reductions increased earnings by $0.10 per share, however, helping to make up for a 10% sales drop at DuPont's (NYSE:DD) agriculture unit, the company's largest business.
    • Net sales fell 9% to $9.17B, primarily due to a decline in volumes and negative currency impacts.
    • DuPont says it's now on track to spin off its performance chemicals unit the middle of this year and expects to report full-year operating earnings at the low end of its $4.00-$4.20 per share range (below analyst projections of $4.46).
    • The results also come just weeks ahead of a shareholder vote on adding nominees from Trian Fund Management, headed by Nelson Peltz, who has argued the company's share value could effectively double if it split itself into three.
    • DD -1.6% premarket
    • Q1 results
    | Tue, Apr. 21, 7:25 AM | 6 Comments
  • Mon, Mar. 23, 12:35 PM
    • Origin Agritech (SEED +24.5%) soars in a move attributed to a WSJ article discussing China's desire to develop a local seed company, potentially through a renewed bid for SEED, which controls the rights to China's first genetically modified corn.
    • SEED last year rejected a $60B takeover bid from China's state-backed Hunan Xindaxin but its top executives believe another attempt is coming, as China looks to find a way to can keep foreign giants such as Monsanto (NYSE:MON), DuPont (NYSE:DD) and Syngenta (NYSE:SYT) at bay while significantly increasing the country’s spending on R&D.
    • China is the world’s second largest seed market but limits foreign producers to minority stakes in joint ventures, and its domestic seed makers are too small and scattered for the government to corral in pursuit of controlling the biotechnology that underpins the competitive power of global seed manufacturers.
    | Mon, Mar. 23, 12:35 PM | 5 Comments
  • Fri, Mar. 20, 7:35 AM
    • JinkoSolar (NYSE:JKS) has signed a strategic collaboration agreement with DuPont (NYSE:DD) to further the growth and adoption of efficient and reliable solar generated electricity.
    • Areas of potential collaboration: technical development, improvements in solar cells and panels and co-marketing efforts.
    • JKS +2.1% premarket
    | Fri, Mar. 20, 7:35 AM | 12 Comments
DD vs. ETF Alternatives
Company Description
E I du Pont de Nemours & Company is a science and engineering company that offers products and patents applications for agriculture, nutrition, electronics and communications, safety and protection, home and construction, transportation and apparel.
Country: United States